Overexpression of CHMP2B suppresses proliferation of renal clear cell carcinoma cells

CHEN Xiaorui; WEI Qingzheng; ZHANG Zongliang; YUAN Jiangshui; SONG Weiqing

doi:10.12122/j.issn.1673-4254.2025.01.16

Abstract：Objective To analyze the association of CHMP2B expression level of with clinicopathological characteristics and prognosis of clear cell renal cell carcinoma(CRCC)and the possible role of CHMP2B in tumorigenesis and progression of CRCC.Methods RNAseq data of CRCC were downloaded from the TCGA database for analysis of CHMP2B expression levels in tumor and adjacent tissues and their correlation with clinicopathological characteristics of the patients.Survival outcomes of the patients with high and low CHMP2B expressions were analyzed using the Kaplan-Meier model,and the COX risk regression model was used for identifying the prognostic factors of the patients.The correlation between CHMP2B expression and immune infiltration,its co-expressed genes,and the effect of CHMP2B gene mutations on immunotherapy responses,and its immunohistochemical expression in CRCC and normal tissues were analyzed.Clinical samples of CRCC were collected to examine CHMP2B expressions using RT-PCR,and cell experiment was carried out to test the effect of CHMP2B overexpression on biological behaviors of CRCC cells.Results CHMP2B was significantly under-expressed in renal cancer tissues,and its overexpression obviously inhibited the proliferation of CRCC cells in vitro.CHMP2B expression level was significantly correlated with age,gender,lymph node metastasis,and tumor stage,and the patients with low CHMP2B expression had poor survival outcomes.Enrichment and co-expression gene analyses suggested that CHMP2B was mainly involved in viral outgrowth,necrotic apoptosis,endocytosis,and immune-regulatory processes in kidney cancer.Conclusion CHMP2B is lowly expressed in renal cancer tissues to affect tumor progression and tumor immune processes,and may serve as a prognostic biomarker and therapeutic target for CRCC.